

**COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-COV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety**

Nicoletta Luxi<sup>1\*</sup>, Alexia Giovanazzi<sup>1\*</sup>, Annalisa Capuano<sup>2</sup>, Salvatore Crisafulli<sup>3</sup>, Paola Maria Cutroneo<sup>4</sup>, Maria Pia Fantini<sup>5</sup>, Carmen Ferrajolo<sup>2</sup>, Ugo Moretti<sup>1</sup>, Elisabetta Poluzzi<sup>6</sup>, Emanuel Raschi<sup>6</sup>, Claudia Ravaldi<sup>7</sup>, Chiara Reno<sup>5</sup>, Marco Tuccori<sup>8</sup>, Alfredo Vannacci<sup>7</sup>, Giovanna Zanoni<sup>9</sup>, Gianluca Trifirò<sup>1\*\*</sup> and IlmiovaccinoCOVID19 collaborating group

1. Department of Diagnostics and Public Health - Section of Pharmacology, University of Verona, Verona, Italy
2. Department of Experimental Medicine - Section of Pharmacology "L. Donatelli", Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania "Luigi Vanvitelli", Naples, Italy
3. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
4. Sicilian Regional Pharmacovigilance Centre, University Hospital of Messina, Messina, Italy
5. Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy
6. Department of Medical and Surgical Science, Alma Mater Studiorum, University of Bologna, Bologna, Italy
7. PeaRL - Perinatal Research Laboratory, NEUROFARBA Department, University of Florence and CiaoLapo Foundation for Perinatal Health; Florence, Italy
8. Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Pisa, Italy
9. Immunology Unit, University Hospital, Verona, Italy

\* Contributed equally to the paper as first authors

\*\* Corresponding author:

Gianluca Trifirò

Email: gianluca.trifiro@univr.it

Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Piazzale L.A. Scuro 10, 37134 Verona

As of July 22, 2021 the following international/national scientific society and regulatory agencies were searched:

- European Medicines Agency. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU. 2021. Available from: <https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu>
- European Medicines Agency. EMA commissions independent research to prepare for real-world monitoring of COVID-19 vaccines. 2020. Available from: <https://www.ema.europa.eu/en/news/ema-commissions-independent-research-prepare-real-world-monitoring-covid-19-vaccines>
- European Medicines Agency. First COVID-19 vaccine approved for children aged 12 to 15 in EU. 2021. Available from: <https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu>

- The American College of Obstetricians and Gynecologists. COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care. 2021. Available from: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care>
- Royal College of Obstetricians & Gynaecologists. COVID-19 vaccines, pregnancy and breastfeeding. 2021. Available from: <https://www.rcog.org.uk/en/guidelines-research-services/coronavirus-covid-19-pregnancy-and-womens-health/covid-19-vaccines-and-pregnancy/covid-19-vaccines-pregnancy-and-breastfeeding/>
- The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Pregnant women are now eligible for the Pfizer COVID-19 vaccine. 2021. Available from: <https://ranzcog.edu.au/news/pregnant-women-are-now-eligible-for-the-pfizer-cov>
- Società Italiana di Ginecologia e Ostetricia. Gravidanza e Vaccinazione anti COVID. 2021. Available from: [https://www.sigo.it/wp-content/uploads/2021/05/PositionPaper\\_Gravidanza\\_Vaccinazione\\_anti\\_COVID\\_05.05.2021.pdf](https://www.sigo.it/wp-content/uploads/2021/05/PositionPaper_Gravidanza_Vaccinazione_anti_COVID_05.05.2021.pdf)
- European Medicines Agency. COVID-19 Vaccine Janssen. 2021. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen>
- European Medicines Agency. Comirnaty. 2021. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty>
- European Medicines Agency. Spikevax (previously COVID-19 Vaccine Moderna). 2021. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax-previously-covid-19-vaccine-moderna>
- European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). 2021. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca>
- American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases. Available from: <https://www.rheumatology.org/Practice-Quality/Clinical-Support/COVID-19-Guidance>
- American College of Allergy, Asthma & Immunology. ACAAI Updates to Guidance on Risk of Allergic Reactions to COVID-19 Vaccines. 2021. Available from: <https://acaai.org/news/acaa-updates-guidance-risk-allergic-reactions-covid-19-vaccines>
- AIFA. FAQ - COVID-19 vaccines. 2021. Available from: <https://www.aifa.gov.it/en/domande-e-risposte-su-vaccini-covid-19>
- European Medicines Agency. Monitoring of COVID-19 medicines. 2021. Available from: <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/monitoring-covid-19-medicines-0>